Advanced Renal Cell Carcinoma Lenvatinib in Combination with Everolimus is approved as a Second-line Therapy

被引：0
|
作者：
Krampe-Scheidler, Anne
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷 / 10期
关键词：
INHIBITOR; E7080;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：666 / 667
页数：2
相关论文
共 50 条
  • [41] Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma
    Motzer, Robert J.
    Barrios, Carlos H.
    Kim, Tae Min
    Falcon, Silvia
    Cosgriff, Thomas
    Harker, W. Graydon
    Srimuninnimit, Vichien
    Pittman, Ken
    Sabbatini, Roberto
    Rha, Sun Young
    Flaig, Thomas W.
    Page, Ray
    Bavbek, Sevil
    Beck, J. Thaddeus
    Patel, Poulam
    Cheung, Foon-yiu
    Yadav, Sunil
    Schiff, Edward M.
    Wang, Xufang
    Niolat, Julie
    Sellami, Dalila
    Anak, Oezlem
    Knox, Jennifer J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (25) : 2766 - +
  • [42] New options for second-line therapy of advanced renal cancer
    Bex, Axel
    LANCET ONCOLOGY, 2013, 14 (06): : 450 - 451
  • [43] Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma
    Glen, Hilary
    FUTURE ONCOLOGY, 2016, 12 (19) : 2195 - 2204
  • [44] Lenvatinib/Everolimus Approved for Use in Advanced Kidney Cancer After Antiangiogenic Therapy
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (06) : 416 - 416
  • [45] Efficacy of the combination of lenvatinib with pembrolizumab in patients with advanced renal cell carcinoma
    Volkova, M., I
    Kalpinskiy, A. S.
    Goncharova, O. A.
    Menshikov, K. V.
    Stativko, O. A.
    Karabina, E. V.
    Dergunov, A. S.
    Polshina, N. I.
    Aleksandrova, E. N.
    Lebedinets, A. A.
    Panov, A. K.
    Sultanbaev, A. V.
    Usynin, E. A.
    Volkonsky, M. V.
    Mikhalyuk, V. V.
    Zukov, R. A.
    Anzhiganova, Yu. V.
    Gusniev, M. A.
    Igumnova, E. N.
    Kuzmicheva, S. V.
    Pokataev, I. A.
    Olshanskaya, A. S.
    Pervakova, N. I.
    Parsadanova, E. L.
    Sannikova, T. A.
    Bystrov, A. A.
    Dubovichenko, D. M.
    Mukhitova, M. R.
    Chubenko, V. A.
    Shkret, K. A.
    Gorshenina, M. N.
    Semenov, A. V.
    Davlatova, M. K.
    Kosareva, A. E.
    Lutoshkina, O. A.
    Maslova, O. A.
    Makhnutina, M. V.
    Mishina, A. V.
    Murzalina, M. Zh.
    Podyacheva, O. A.
    Kalinin, S. A.
    Mailyan, O. A.
    Safarova, A. R.
    Semenova, K. O.
    Strokova, M. A.
    Urashkina, E. Yu.
    Shmygina, O. S.
    Novikova, O. Yu.
    ONKOUROLOGIYA, 2024, 20 (03):
  • [46] Nivolumab: The New Second Line Treatment for Advanced Renal-cell Carcinoma Commentary on: Nivolumab Versus Everolimus in Advanced Renal-cell Carcinoma
    Chedgy, Edmund C. P.
    Black, Peter C.
    UROLOGY, 2016, 89 : 8 - 9
  • [47] Combination of Gemcitabine and Paclitaxel as Second-line Chemotherapy for Advanced Urothelial Carcinoma
    Suyama, Takahito
    Ueda, Takeshi
    Fukasawa, Satoshi
    Imamura, Yusuke
    Nakamura, Kazuyoshi
    Miyasaka, Kyoko
    Sazuka, Tomokazu
    Egoshi, Ken-ichi
    Nihei, Naoki
    Hamano, Masaaki
    Ichikawa, Tomohiko
    Maruoka, Masayuki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (04) : 244 - 250
  • [48] Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma
    Wang, Ye
    Wang, Hao
    Yi, Manman
    Han, Zhou
    Li, Li
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [49] Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma
    Goebell, Peter J.
    Ivanyi, Philipp
    Bedke, Jens
    Bergmann, Lothar
    Berthold, Dominik
    Boegemann, Martin
    Busch, Jonas
    Doehn, Christian
    Krege, Susanne
    Retz, Margitta
    Amsberg, Gunhild von
    Grimm, Marc-Oliver
    Gruenwald, Viktor
    FUTURE ONCOLOGY, 2020, 16 (29) : 2307 - 2328
  • [50] Efficacy and safety of second-line cabozantinib after immuno-oncology combination therapy for advanced renal cell carcinoma: Japanese multicenter retrospective study
    Sazuka, Tomokazu
    Matsushita, Yuto
    Sato, Hiroaki
    Osawa, Takahiro
    Hinata, Nobuyuki
    Hatakeyama, Shingo
    Numakura, Kazuyuki
    Ueda, Kosuke
    Kimura, Takahiro
    Takahashi, Masayuki
    Tanaka, Hajime
    Kawasaki, Yoshihide
    Kurahashi, Toshifumi
    Kato, Takuma
    Fujita, Kazutoshi
    Miyake, Makito
    Kojima, Takahiro
    Kitamura, Hiroshi
    Miyake, Hideaki
    Ichikawa, Tomohiko
    SCIENTIFIC REPORTS, 2023, 13 (01):
12345